CLINICAL TRIALS AND OBSERVATIONS Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)
نویسندگان
چکیده
Hagop M. Kantarjian,1 Neil P. Shah,2 Jorge E. Cortes,1 Michele Baccarani,3 Mohan B. Agarwal,4 María Soledad Undurraga,5 Jianxiang Wang,6 Juan Julio Kassack Ipiña,7 Dong-Wook Kim,8 Michinori Ogura,9 Carolina Pavlovsky,10 Christian Junghanss,11 Jorge H. Milone,12 Franck E. Nicolini,13 Tadeusz Robak,14 Jan Van Droogenbroeck,15 Edo Vellenga,16 M. Brigid Bradley-Garelik,17 Chao Zhu,17 and Andreas Hochhaus18
منابع مشابه
Regular Article CLINICAL TRIALS AND OBSERVATIONS Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)
Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION) Elias Jabbour, Hagop M. Kantarjian, Giuseppe Saglio, Juan Luis Steegmann, Neil P. Shah, Concepción Boqué, Charles Chuah, Carolina Pavlovsky, Jiřı́ Mayer, Jorge Cortes, Michele Baccarani, Dong-Wook Kim, M. Brigid Bradley-Garelik, Hesham Mohamed, Mark Wildgust, and And...
متن کاملCLINICAL TRIALS AND OBSERVATIONS The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up
Responses can be achieved with dasatinib or nilotinib after failure of 2 prior tyrosine kinase inhibitors (TKIs). We report on 48 chronic myeloid leukemia patients sequentially treated with 3 TKIs: 34 with dasatinib after imatinib/nilotinib failure and 14 with nilotinib after imatinib/ dasatinib failure. Before the third TKI, 25 patients were in chronic phase (CP), 10 in accelerated phase (AP),...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up
1M. D. Anderson Cancer Center, Houston, TX; 2St Mary’s Hospital, Seoul, South Korea; 3Hospital das Clinicas, Sao Paulo, Brazil; 4Hospital De Clinicas De Curitiba, Curitiba, Brazil; 5Washington University School of Medicine, St Louis, MO; 6Medizinische Fakultaet Mannheim, University of Heidelberg, Heidelberg, Germany; 7Fred Hutchinson Cancer Research Center, Seattle, WA; 8Emory University School...
متن کاملRegular Article CLINICAL TRIALS AND OBSERVATIONS Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities
• This analysis demonstrates the universality of the early response in CML, regardless of the treatment modality used. • Factors correlating with poor cytogenetic responses at 3-mo assessment in a multivariate analysis across all 4 TKIs. Early responses to tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML)-chronic phase (CP) are associated with improved outcome. We analyzed the...
متن کاملRegular Article CLINICAL TRIALS AND OBSERVATIONS Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study
University of California at San Francisco School of Medicine, San Francisco, CA; INSERM Clinical Investigation Center 1402, Centre Hospitalier et Universitaire de Poitiers, Université de Poitiers, Poitiers, France; The University of Texas MD Anderson Cancer Center, Houston, TX; Karmanos Cancer Institute, Wayne State University, Detroit, MI; Charité, Campus Virchow Klinikum, Universitätsmedizin ...
متن کامل